Skip to Content
  • MyChart

    Log in to our secure, personalized website to manage your care (formerly myMDAnderson).

  • Request an Appointment

    If you are ready to make an appointment, select a button on the right. If you have questions about UT MD Anderson’s appointment process, our information page may be the best place to start.

    Appointment Information
    New Patients Current Patients Referring Physicians
  • Every Breakthrough
    Begins With You

    Gifts to UT MD Anderson’s historic philanthropic campaign help accelerate discovery, transform lives and bring hope to more patients than ever before.

    Learn more about Only Possible Here
    Donate Today only-possible-here-logo
The University of Texas MD Anderson Cancer Center
  • Clinical Trials
  • Locations
  • Careers
  • Contact Us
  • Our Doctors
    • Español
    • عربى
    • 中文
    • Türkçe
Clear
close
      MyChart
      Donate Today
      • Clinical Trials
      • Locations
      • Careers
      • Contact Us
        • Español
        • عربى
        • 中文
        • Türkçe
      • Request an Appointment
      • New Patients
      • Current Patients
      • Referring Physicians
      • Patients & Family
          • Becoming Our Patient Home
          • Why UT MD Anderson
          • Planning for Care
          • Getting to UT MD Anderson
          • While You're Here
          • International Center
          • Services and Amenities
          • Insurance & Billing
          • Second Opinion Appointments
          • Diagnosis & Treatment Home
          • Cancer Types
          • A New Diagnosis
          • Treatment Options
          • Care Centers & Clinics
          • Emotional & Physical Effects
          • Patient Support
          • Clinical Trials
          • Supporting a Loved One Home
          • Caregiver Roles & Challenges
          • Children and Teens
          • Taking Care of Yourself
          • Helping a UT MD Anderson Patient
          • Dealing with Loss
          • Life After Cancer Home
          • Follow-up Care After Cancer Treatment
          • Long-Term Effects of Cancer
          • Social & Emotional Impacts of Cancer
          • Legal & Financial Impacts of Cancer
          • Survivorship Week
        • Request an Appointment Current Patients

          Find information and resources for current and returning patients.

          Clinical Trials

          Learn about clinical trials at UT MD Anderson and search our database for open studies.

      • Prevention & Screening
          • Manage Your Risk Home
          • Tobacco Control
          • Diet
          • Body Weight
          • Physical Activity
          • Skin Safety
          • HPV
          • Hepatitis
          • Alcohol
          • Family History Home
          • Genetic Testing
          • Hereditary Cancer Syndromes
          • Genetic Counseling and Testing FAQs
          • Cancer Screenings Home
          • Mammograms & Breast Cancer Screening
          • Cervical Cancer Screening
          • Colorectal Cancer Screening
          • Endometrial Cancer Screening
          • Liver Cancer Screening
          • Lung Cancer Screening
          • Mobile Mammography
          • Ovarian Cancer Screening
          • Prostate Cancer Screening
          • Skin Cancer Screening
          • Women's Cancer Screening
          • Men's Cancer Screening
        • Cancer Prevention Center 

          The Lyda Hill Cancer Prevention Center provides cancer risk assessment, screening and diagnostic services.

      • Donors & Volunteers
          • Donate Home
          • Raise Money
          • Honor Loved Ones
          • Create Your Legacy
          • Endowments
          • Caring Fund
          • Matching Gifts
          • Foundation and Corporation Relations
          • Volunteer Home
          • Why Volunteer
          • On-Site Volunteers
          • Volunteer Endowment
          • Patient Experience
          • Teen Volunteer Leadership Program
          • Children's Cancer Hospital Councils
          • Other Ways to Help Home
          • Give Blood
          • Shop UT MD Anderson
          • Children's Art Project
          • Donate Goods or Services
          • Attend Events
          • Cord Blood Bank
          • Corporate Alliances Home
          • Current Alliances
        • Join the Campaign to End Cancer 

          Help us celebrate and fuel the groundbreaking innovations and transformative advancements that define UT MD Anderson.

      • For Physicians
          • Refer a Patient Home
          • Health Care Provider Resource Center
          • Referring Provider Team
          • Insurance Information
          • International Referrals
          • myMDAnderson for Physicians
          • Second Opinion Pathology
          • Clinical Trials Home
          • Clinical Tools & Resources Home
          • Clinical Calculators
          • Clinical Practice Algorithms
        • myMDAnderson for Physicians 

          Our personalized portal helps you refer your patients and communicate with their UT MD Anderson care team.

      • Research
          • Departments, Labs and Institutes Home
          • Departments and Divisions
          • Labs
          • Research Centers and Programs
          • Institutes
          • Specialized Programs of Research Excellence (SPORE) Grants
          • Research Areas Home
          • Basic Science
          • Translational Research
          • Clinical Research
          • Prevention & Personalized Risk Assessment
          • Research Resources Home
          • Excellence in Science
          • Core Facilities and Services
          • Conferences & Seminars
          • Why Research at UT MD Anderson
          • STRIDE
          • NCI-Designated Cancer Center
          • Data Resources
        • Clinical Trials 

          As part of our mission to eliminate cancer, UT MD Anderson researchers conduct hundreds of clinical trials to test new treatments for both common and rare cancers.

      • Education & Training
          • Degree-Granting Schools Home
          • School of Health Professions
          • MD Anderson UTHealth Houston Graduate School
          • Research Training Home
          • Early Career Pathway Programs
          • Predoctoral Training
          • Postdoctoral Training
          • Mentored Faculty Programs
          • Career Development
          • Clinical Training Home
          • Graduate Medical Education
          • Clinical Education for Non-Physicians
          • Nursing Education & Training
          • Continuing Education & Review Courses
          • Simulation Center
          • Continuing Education & Professional Development Home
          • Continuing Professional Education/Conferences
          • Administrative Internships & Fellowships
          • Cancer Survivorship Professional Education
          • Leadership Institute
          • Patient Home Visits
          • Education Resources Home
          • Alumni Relations
          • Education Design Services
          • Awards & Recognitions
          • Academic Mentoring Council
          • Why UT MD Anderson & Houston
          • Outreach Programs Home
          • Project ECHO
          • Observer Programs
          • Comparative Effectiveness Training (CERTaIN)
          • Faculty Speakers Bureau
        • Apply to SHP

          Choose from 12 allied health programs at School of Health Professions.

          Research Trainees

          View open postdoctoral and other research trainee positions.

          GME Fellowships

          Learn about our graduate medical education residency and fellowship opportunities.

      Jian Hu Image

      Jian Hu

      Department of Cancer Biology, Division of Discovery Science

      Present Title & Affiliation

      Primary Appointment

      Professor, Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX

      Dual/Joint/Adjunct Appointment

      Felix L Haas Endowed Professor in Basic Science, Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas

      Professor, Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX

      Education & Training

      Degree-Granting Education

      2007University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, US, Biochemistry and Biophysics, Ph.D
      2002Fudan Medical School, Shanghai Cancer Center, Shanghai, CN, Molecular Biology, M.S
      1999Fudan University, Shanghai, CN, Biology, BS

      Postgraduate Training

      2011-2014Instructor, UT MD Anderson Cancer Center, Houston, Texas
      2007-2011Postdoctoral Fellow, Cancer Genetics, Dana Farber Cancer Center, Harvard Medical School, Boston, Massachusetts

      Experience & Service

      Administrative Appointments/Responsibilities

      Scientific Director, High Resolution Electron Microscopy Facility, The University of Texas MD Anderson Cancer Center, Houston, TX, 2024 - Present

      Scientific Director, Cancer Neuroscience Program, The University of Texas MD Anderson Cancer Center, Houston, TX, 2023 - Present

      Director, Cancer Biology Program, The University of Texas MD Anderson Cancer Center (GSBS), Houston, TX, 2022 - Present

      Other Professional Positions

      Course Director, Cancer Neuroscience, MD Anderson Cancer Center and UT Health Houston Graduate School of Biomedical Sciences (GSBS), Houston, TX, 2023 - Present

      Director, Program Directors Committee,MD Anderson Cancer Center and UT Health Houston Graduate School of Biomedical Sciences (GSBS), Houston, TX, 2022 - Present

      Course Director, Biology of Neurological Diseases, MD Anderson Cancer Center and UT Health Houston Graduate School of Biomedical Sciences (GSBS), Houston, TX, 2022 - Present

      Chair, Teaching Academy Sub-Committee, MD Anderson Graduate and Education Committee, Houston, TX, 2021 - Present

      Executive Committee Member, GSBS Executive Committee, Houston, TX, 2021 - Present

      Executive Committee Member, MD Anderson Cancer Center Brain Tumor Center Member, MD Anderson Cancer Center, Houston, TX, 2018 - Present

      Course Director, Basic and Translational Cancer Biology, MD Anderson Cancer Center and UT Health Houston Graduate School of Biomedical Sciences (GSBS), Houston, TX, 2018 - Present

      Director, Departmental Lab Meeting Series, Department of Cancer Biology, Department of Genomic Medicine, and Therapeutic Platform, MD Anderson Cancer Center,, Houston, 2015 - Present

      Director, Departmental Seminar Series, Department of Cancer Biology, MD Anderson Cancer Center, Houston, TX, 2015 - Present

      Extramural Institutional Committee Activities

      Member, Faculty Recruitment Committee, The University of Texas MD Anderson Cancer Center, 2024 - Present

      Member, Promotion and Tenure Committee, The University of Texas MD Anderson Cancer Center, 2024 - 2027

      Committee Member, Bridge Fund, The University of Texas MD Anderson Cancer Center, 2020 - Present

      Executive Committee Member, MD Anderson/UT Health Graduate School (GSBS), The University of Texas MD Anderson Cancer Center, 2020 - Present

      Co-chair, Brain Tumor Center Distinguished Lectureship, The University of Texas MD Anderson Cancer Center, 2019 - Present

      Committee Member, MD Anderson Cancer Center Brain Tumor Center Executive Committee, The University of Texas MD Anderson Cancer Center, 2018 - Present

      Honors & Awards

      2024Dallas/Fort-Worth Living Legend Award for Basic Science, MD Anderson Cancer Center
      2023President's Recognition of Faculty Excellence - Education & Mentorship Advancement
      2022John P. Mc Govern Award for Outstanding Teaching, MD Anderson/UT Health Graduate School (GSBS)
      2021Commended Course Director (Cancer Biology Core Course), MD Anderson/UT Health Graduate School (GSBS)
      2021President's Recognition of Faculty Excellence - Education & Mentorship Advancement
      2020 - 2022Andrew Sabin Family Fellowship Award, Andrew Sabin Family Foundation
      2020 - 2022MD Anderson Faculty Scholar Award, MD Anderson Cancer Center
      2019Young Investigators Forum, Society of Neuro-Oncology
      2018Cancer Stem Cell Young Investigator Award, Cancer Stem Cell Conference (CSC)
      2018Young Investigator MERIT Award (R37), NCI
      2018John P. McGovern Award for Outstanding Teaching, MD Anderson UTHealth Graduate School (GSBS)
      2017 - 2021Distinguished Scientist Award, Sontag Foundation
      2017American Cancer Society Research Scholar Award, MD Anderson Cancer Center
      2017Wall of Science Award, MD Anderson Cancer Center
      2016 - 2018Sidney Kimmel Scholar Award, The Sidney Kimmel Foundation for Cancer Research
      2015Young Investigator Workshop (Brain Tumor) Travel Award, Oslo University Hospital and MD Anderson Cancer Center
      2015CCSG New Faculty Award, UT MD Anderson
      2014 - 2017Rising STARS Award, Science and Technology Acquisition and Retention Program, The University of Texas System
      2014 - 2015Broach Scholar Award, The Broach Foundation
      2014Brain Cancer SPORE Career Development Award, NCI
      2013 - 2018K99/R00 Pathway to Independence Award, NIH
      2013Travel Award on Adult Stem Cells in Aging Diseases and Cancer, V. Else Kröner-Fresenius Symposium, Eisenach, Germany
      20117th Annual Postdoc/Graduate Student Retreat, Best Oral Presentation Award, Dana Farber Cancer Center
      2008 - 2011Fellow Award, Leukemia and Lymphoma Society
      2006Graduate Fellow Award, Best Graduate Student Award, Lineberger Cancer Center, University of North Carolina at Chapel Hill
      2005Travel Award: Ubiquitin and Signaling, Taos, New Mexico, Keystone Symposium
      2004Best Poster Award for Chinese Scholar Association of United States, Durham, North Carolina
      2002Guanghua Scholarship, Fudan Medical School
      1999Zengshou Scholarship, Fudan University

      Grant & Contract Support

      Date: 2024 - 2027
      Title:Tackling cancer therapy-induced central nervous system deficits
      Funding Source:Kleberg Foundation Award
      Role:PI
      Date: 2024 - 2025
      Title:Define the unique features of nervous system immunology in context of cancer and age
      Funding Source:Cancer Neuroscience Initiative
      Role:PI
      Date: 2024 - 2029
      Title:Restore Myeloid Phagocytosis in Glioblastoma by Targeting the QKI/PPARb/RXRa Complex
      Funding Source:NIH/NCI
      Role:PI
      ID:2P50CA127001
      Date: 2023 - 2028
      Title:The role of membrane homeostasis of neural stem cell and glioma stem cells in neural development and gliomagenesis
      Funding Source:NIH/NINDS
      Role:PI
      ID:1R01NS132944
      Date: 2023 - 2028
      Title:Targeting Epigenetic Machinery to Overcome Myeloid Cell-Mediated Resistance to Anti-PD-1 Therapy in GBM
      Funding Source:NIH/NCI
      Role:Co-I
      ID:1R37CA279192
      Date: 2023 - 2027
      Title:Normalizing membrane homeostasis in microglia/macrophages of pediatric high-grade gliomas
      Funding Source:Cancer Prevention & Research Institute of Texas (CPRIT)
      Role:PI
      ID:RP230154
      Date: 2022 - 2027
      Title:Promoting remyelination in multiple sclerosis by simultaneously modulation myelin debris clearance and myelin lipid synthesis
      Funding Source:NIH/NINDS
      Role:PI
      ID:1R01NS127933
      Date: 2022 - 2024
      Title:Restoration of Phagocytosis Function of Glioma-Associated Microglia/Macrophage by Activating QKI-PPARb-RXRa
      Funding Source:Cancer Prevention & Research Institute of Texas (CPRIT)
      Role:PI
      ID:RP220592
      Date: 2022 - 2026
      Title:Epigenetic regulation of alternative lengthening of telomeres (ALT) in pediatric high-grade gliomas
      Funding Source:Cancer Prevention & Research Institute of Texas (CPRIT)
      Role:PI
      ID:RP220360
      Date: 2022 - 2027
      Title:Membrane Biology of Glioma-Associated Microglia/Macrophages
      Funding Source:Break Through Cancer
      Role:PI
      Date: 2021 - 2026
      Title:Investigating the role of dysfunctional histone H3.3 in driving early neuronal development and pediatric high-grade gliomas
      Funding Source:NIH/NINDS
      Role:PI
      ID:1R01NS119493
      Date: 2021 - 2026
      Title:Systematic dissection of function and mechanism of long non-coding RNAs in glioblastoma
      Funding Source:NIH/NINDS
      Role:Co-I
      ID:1R01NS117668

      Selected Publications

      Peer-Reviewed Articles

      1. Yu, K, Basu, S, Baquer, G, Ahn, R, Gantchev, J, Jindal, S, Regan, MS, Abou-Mrad, Z, Prabhu, MC, Williams, MJ, D’Souza, AD, Malinowski, S, Hopland, K, Elhanati, Y, Stopka, SA, Stortchevoi, A, Couturier, C, He, Z, Sun, JJ, Chen, Y, Espejo, A, Chow, KH, Yerrum, S, Kao, PL, Kerrigan, BP, Norberg, L, Nielsen, D, Douville, C, Sharma, P, Giantini-Larsen, AM, Hu, J, Ayoub, G, Elharouni, D, Polk, MJ, Landivar, AM, Masud, N, Ling, AL, Triggs, D, Piranlioglu, R, Ball, A, Soni, H, Solomon, IH, Vasquez, KL, Vogelzang, J, Puduvalli, VK, Huse, J, Kim, YB, Goswami, S, Lang Jr, FF, Sharma, P. Investigative needle core biopsies support multimodal deep-data generation in glioblastoma. Nature communications 16(1), 2025. e-Pub 2025. PMID: 40295505.
      2. Freitas-Cortez, MA, Masrorpour, F, Jiang, H, Mahmud, I, Lu, Y, Huang, A, Duong, LK, Wang, Q, Voss, TA, Kettlun Leyton, C, Wei, B, Chan, W, Lin, H, Zhang, J, Tsouko, E, Ganjoo, S, Barsoumian, H, Riad, TS, Hu, Y, Leuschner, C, Puebla-Osorio, N, Wang, J, Hu, J, Davies, MA, Puduvalli, VK, Billon, C, Burris, TP, Lorenzi, PL, Gan, B, Welsh, J. Cancer cells avoid ferroptosis induced by immune cells via fatty acid binding proteins. Molecular cancer 24(1), 2025. e-Pub 2025. PMID: 39901247.
      3. Ling, AL, Gantchev, J, Prabhu, MC, Basu, S, Ahn, R, Holdhoff, M, Masud, N, Ball, A, Nikas, O, Villa, GR, Regan, MS, Baquer, G, Ayoub, G, Whittaker, CA, Abou-Mrad, Z, Santos, A, Couturier, C, Elharouni, D, Vogelzang, J, Yu, K, Chen, H, He, Z, Jiang, W, Lucas, CG, Sax, HE, Lang Jr, FF, Puduvalli, VK, Tabar, V, Brennan, CW, Boire, A, Holdhoff, M, Bettegowda, C, Cima, M, Solomon, IH, Yuan, Y, Tak, PP, Sharma, P, White, F, Ligon, KL, Agar, NY, Espejo, A, Sun, JJ, Chen, Y, Jindal, S, Huse, J, Goswami, S, Akdemir, KC, Hu, J, Sharma, P, Buchold, G. Serial multiomics uncovers anti-glioblastoma responses not evident by routine clinical analyses. Science translational medicine 17(819), 2025. e-Pub 2025. PMID: 41061048.
      4. Huang, Z, Ren, X, Hu, J. Drosha. Genes and Development 39(11-12):677-678, 2025. e-Pub 2025. PMID: 40345854.
      5. Kim, KS, Habashy, KJ, Gould, A, Zhao, J, Najem, H, Amidei, C, Saganty, R, Arrieta, VA, Dmello, C, Chen, L, Zhang, DY, Castro, BA, Billingham, L, Levey, DL, Huber, O, Marques, M, Savitsky, DA, Morin, BM, Muzzio, M, Canney, M, Horbinski, C, Zhang, P, Miska, J, Padney, S, Zhang, B, Rabadan, R, Phillips, JJ, Butowski, N, Heimberger, AB, Hu, J, Stupp, R, Chand, D, Lee-Chang, C, Sonabend, AM. Fc-enhanced anti-CTLA-4, anti-PD-1, doxorubicin, and ultrasound-mediated blood-brain barrier opening. Neuro-oncology 26(11):2044-2060, 2024. e-Pub 2024. PMID: 39028616.
      6. Min, KW, Choi, KM, Mun, H, Ko, S, Lee, JW, Sagum, C, Bedford, MT, Kim, YK, Delaney, JR, Cho, JH, Dawson, TM, Dawson, VL, Twal, W, Kim, DC, Panganiban, CH, Lang, H, Zhou, X, Shin, S, Hu, J, Heise, T, Kwon, SH, Kim, D, Kim, YH, Kang, SU, Kim, K, Lewis, S, Eroglu, A, Ryu, S, Kim, D, Chang, JH, Jung, J, Yoon, JH. Mature microRNA-binding protein QKI suppresses extracellular microRNA let-7b release. Journal of cell science 137(21), 2024. e-Pub 2024. PMID: 39308343.
      7. Kim KS, Zhang J, Arrieta VA, Dmello C, Grabis E, Habashy K, Duffy J, Zhao J, Gould A, Chen L, Hu J, Balyasnikova I, Chand D, Levey D, Canoll P, Zhao W, Sims PA, Rabadan R, Pandey S, Zhang B, Lee-Chang C, Heiland DH, Sonabend AM. MAPK/ERK signaling in gliomas modulates interferon responses, T cell recruitment, microglia phenotype, and immune checkpoint blockade efficacy. bioRxiv, 2024. e-Pub 2024. PMID: 39345374.
      8. Najem, H, Lea, ST, Tripathi, S, Hurley, LA, Chen, CH, William, I, Sooreshjani, M, Bowie, M, Hartley, G, Dussold, C, Pacheco, S, Dmello, C, Lee-Chang, C, McCortney, K, Steffens, A, Walshon, J, Ott, M, Wei, J, Marisetty, AL, Balyasnikova, IV, Stupp, R, Lukas, RV, Hu, J, James, CD, Horbinski, C, Lesniak, MS, Ashley, DM, Priebe, W, Platanias, LC, Curran, M, Heimberger, AB. STING agonist 8803 reprograms the immune microenvironment and increases survival in preclinical models of glioblastoma. Journal of Clinical Investigation 134(12), 2024. e-Pub 2024. PMID: 38941297.
      9. Pan, Y, Hu, J. Hormonal basis of brain fog in cancer treatment. Journal of Experimental Medicine 221(5), 2024. e-Pub 2024. PMID: 38597926.
      10. Fan, H, Song, L, Fan, J, Ma, J, Li, X, Zhang, J, Hu, J, Wu, Z, Zhang, D, Wang, L. Decoding meningioma heterogeneity and neoplastic cell—macrophage interaction through single-cell transcriptome profiling across pathological grades. Journal of translational medicine 21(1), 2023. e-Pub 2023. PMID: 37880655.
      11. Fan, H, Song, L, Fan, J, Ma, J, Li, X, Zhang, J, Hu, J, Wu, Z, Zhang, D, Wang, L. Decoding meningioma heterogeneity and neoplastic cell—macrophage interaction through single-cell transcriptome profiling across pathological grades. Journal of translational medicine 21(1), 2023. e-Pub 2023. PMID: 37880655.
      12. Fan, H, Song, L, Fan, J, Ma, J, Li, X, Zhang, J, Hu, J, Wu, Z, Zhang, D, Wang, L. Decoding meningioma heterogeneity and neoplastic cell—macrophage interaction through single-cell transcriptome profiling across pathological grades. Journal of translational medicine 21(1), 2023. e-Pub 2023. PMID: 37880655.
      13. Chen, CH, Chin, R, Hartley, G, Lea, ST, Engel, BJ, Hsieh, CE, Prasad, R, Roszik, J, Shingu, T, Lizee, GA, Heimberger, AB, Millward, S, Hu, J, Hong, DS, Curran, M. Novel murine glioblastoma models that reflect the immunotherapy resistance profile of a human disease. Neuro-oncology 25(8):1415-1427, 2023. e-Pub 2023. PMID: 36705543.
      14. Zheng, C, Wei, Y, Zhang, Q, Sun, M, Wang, Y, Hou, J, Zhang, P, Lv, X, Su, D, Jiang, Y, Gumin, J, Sahni, N, Hu, B, Wang, W, Chen, X, McGrail, DJ, Zhang, C, Huang, S, Xu, H, Chen, J, Lang Jr, FF, Hu, J, Chen, Y. Multiomics analyses reveal DARS1-AS1/YBX1–controlled posttranscriptional circuits promoting glioblastoma tumorigenesis/radioresistance. Science Advances 9(31), 2023. e-Pub 2023. PMID: 37540752.
      15. Zamler, D, Hu, J. Primitive Oligodendrocyte Precursor Cells Are Highly Susceptible to Gliomagenic Transformation. Cancer Research 83(6):807-808, 2023. e-Pub 2023. PMID: 36919423.
      16. Cata, JP, Hu, J, Feng, L, Chung, C, Woodman, SE, Meyer, LA. Association between COVID-19 and Postoperative Neurological Complications and Antipsychotic Medication Use after Cancer Surgery. Journal of Personalized Medicine 13(2), 2023. e-Pub 2023. PMID: 36836508.
      17. Sun, C, Ye, Y, Tan, Z, Liu, Y, Li, Y, Hu, W, Liang, K, Egranov, SD, Huang, L, Zhang, Z, Zhang, Y, Yao, J, Nguyen, TK, Zhao, Z, Wu, A, Marks, JR, Caudle, AS, Sahin, AA, Gao, J, Gammon, ST, Piwnica-Worms, D, Hu, J, Chiao, PJ, Yu, D, Hung, MC, Curran, M, Calin, GA, Ying, H, Han, L, Lin, C, Yang, L. Tumor-associated nonmyelinating Schwann cell-expressed PVT1 promotes pancreatic cancer kynurenine pathway and tumor immune exclusion. Science Advances 9(5), 2023. e-Pub 2023. PMID: 36724291.
      18. Cheng, Y, Shen, Z, Gao, Y, Chen, F, Xu, H, Mo, Q, Chu, X, Peng, Cl, McKenzie, T, Palacios, BE, Hu, J, Zhou, H, Long, J. Phase transition and remodeling complex assembly are important for SS18-SSX oncogenic activity in synovial sarcomas. Nature communications 13(1), 2022. e-Pub 2022. PMID: 35585082.
      19. Zamler DB, Shingu T, Kahn LM, Huntoon K, Kassab C, Ott M, Tomczak K, Liu J, Li Y, Lai I, Zorilla-Veloz R, Yee C, Rai K, Kim BY, Watowich SS, Heimberger AB, Draetta GF, Hu J. Immune landscape of a genetically engineered murine model of glioma compared with human glioma. JCI Insight 7(12), 2022. e-Pub 2022. PMID: 35653194.
      20. Rao, R, Han, R, Ogurek, S, Xue, C, Wu, LN, Zhang, L, Zhang, L, Hu, J, Phoenix, T, Waggoner, SN, Lu, QR. Glioblastoma genetic drivers dictate the function of tumor-Associated macrophages/microglia and responses to CSF1R inhibition. Neuro-oncology 24(4):584-597, 2022. e-Pub 2022. PMID: 34562087.
      21. Aksoy Yasar FB, Shingu T, Zamler DB, Zaman MF, Chien DL, Zhang Q, Ren J, Hu J. Quaking but not parkin is the major tumor suppressor in 6q deleted region in glioblastoma. Front Cell Dev Biol 10:931387, 2022. e-Pub 2022. PMID: 36051438.
      22. Sabbagh A, Beccaria K, Ling X, Marisetty A, Ott M, Caruso H, Barton E, Kong LY, Fang D, Latha K, Zhang DY, Wei J, DeGroot J, Curran MA, Rao G, Hu J, Desseaux C, Bouchoux G, Canney M, Carpentier A, Heimberger AB. Opening of the Blood-Brain Barrier Using Low-Intensity Pulsed Ultrasound Enhances Responses to Immunotherapy in Preclinical Glioma Models. Clin Cancer Res 27(15):4325-4337, 2021. e-Pub 2021. PMID: 34031054.
      23. Shaim H, Shanley M, Basar R, Daher M, Gumin J, Zamler DB, Uprety N, Wang F, Huang Y, Gabrusiewicz K, Miao Q, Dou J, Alsuliman A, Kerbauy LN, Acharya S, Mohanty V, Mendt M, Li S, Lu J, Wei J, Fowlkes NW, Gokdemir E, Ensley EL, Kaplan M, Kassab C, Li L, Ozcan G, Banerjee PP, Shen Y, Gilbert AL, Jones CM, Bdiwi M, Nunez-Cortes AK, Liu E, Yu J, Imahashi N, Muniz-Feliciano L, Li Y, Hu J, Draetta G, Marin D, Yu D, Mielke S, Eyrich M, Champlin RE, Chen K, Lang FF, Shpall EJ, Heimberger AB, Rezvani K. Targeting the alphav integrin/TGF-beta axis improves natural killer cell function against glioblastoma stem cells. J Clin Invest 131(14), 2021. e-Pub 2021. PMID: 34138753.
      24. Shin S, Zhou H, He C, Wei Y, Wang Y, Shingu T, Zeng A, Wang S, Zhou X, Li H, Zhang Q, Mo Q, Long J, Lan F, Chen Y, Hu J. Qki activates Srebp2-mediated cholesterol biosynthesis for maintenance of eye lens transparency. Nat Commun 12(1):3005, 2021. e-Pub 2021. PMID: 34021134.
      25. Zhou X, Shin S, He C, Zhang Q, Rasband MN, Ren J, Dai C, Zorrilla-Veloz RI, Shingu T, Yuan L, Wang Y, Chen Y, Lan F, Hu J. Qki regulates myelinogenesis through Srebp2-dependent cholesterol biosynthesis. Elife 10, 2021. e-Pub 2021. PMID: 33942715.
      26. Ren J, Dai C, Zhou X, Barnes JA, Chen X, Wang Y, Yuan L, Shingu T, Heimberger AB, Chen Y, Hu J. Qki is an essential regulator of microglial phagocytosis in demyelination. J Exp Med 218(1), 2021. e-Pub 2021. PMID: 33045062.
      27. Cui M, Zorrilla-Veloz RI, Hu J, Guan B, Ma X. Diagnostic Accuracy of PET for Differentiating True Glioma Progression From Post Treatment-Related Changes: A Systematic Review and Meta-Analysis. Front Neurol 12:671867, 2021. e-Pub 2021. PMID: 34093419.
      28. Chiang ACA, Seua AV, Singhmar P, Arroyo LD, Mahalingam R, Hu J, Kavelaars A, Heijnen CJ. Bexarotene normalizes chemotherapy-induced myelin decompaction and reverses cognitive and sensorimotor deficits in mice. Acta Neuropathol Commun 8(1):193, 2020. e-Pub 2020. PMID: 33183353.
      29. Ott M, Tomaszowski KH, Marisetty A, Kong LY, Wei J, Duna M, Blumberg K, Ji X, Jacobs C, Fuller GN, Langford LA, Huse JT, Long JP, Hu J, Li S, Weinberg JS, Prabhu SS, Sawaya R, Ferguson S, Rao G, Lang FF, Curran MA, Heimberger AB. Profiling of patients with glioma reveals the dominant immunosuppressive axis is refractory to immune function restoration. JCI Insight 5(17), 2020. e-Pub 2020. PMID: 32721947.
      30. Zhou X, He C, Ren J, Dai C, Stevens SR, Wang Q, Zamler D, Shingu T, Yuan L, Chandregowda CR, Wang Y, Ravikumar V, Rao AU, Zhou F, Zheng H, Rasband MN, Chen Y, Lan F, Heimberger AB, Segal BM, Hu J. Mature myelin maintenance requires Qki to coactivate PPARβ-RXRα-mediated lipid metabolism. J Clin Invest 130(5):2220-2236, 2020. e-Pub 2020. PMID: 32202512.
      31. Chen D, Li G, Ji C, Lu Q, Qi Y, Tang C, Xiong J, Hu J, Yasar FBA, Zhang Y, Hoon DSB, Yao Y, Zhou L. Enhanced B7-H4 expression in gliomas with low PD-L1 expression identifies super-cold tumors. J Immunother Cancer 8(1), 2020. e-Pub 2020. PMID: 32457124.
      32. Li F, Deng Z, Zhang L, Wu C, Jin Y, Hwang I, Vladimirova O, Xu L, Yang L, Lu B, Dheekollu J, Li JY, Feng H, Hu J, Vakoc CR, Ying H, Paik J, Lieberman PM, Zheng H. ATRX loss induces telomere dysfunction and necessitates induction of alternative lengthening of telomeres during human cell immortalization. EMBO J:e96659. e-Pub 2019. PMID: 31454099.
      33. Yao Y, Luo F, Tang C, Chen D, Qin Z, Hua W, Xu M, Zhong P, Yu S, Chen D, Ding X, Zhang Y, Zheng X, Yang J, Qian J, Deng Y, Hoon DSB, Hu J, Chu Y, Zhou L. Molecular subgroups and B7-H4 expression levels predict responses to dendritic cell vaccines in glioblastoma: an exploratory randomized phase II clinical trial. Cancer Immunol Immunother 67(11):1777-1788, 2018. e-Pub 2018. PMID: 30159779.
      34. Chen D, Chen D, Cao D, Hu J, Yao Y. A signature based on survival-related genes identifies high-risk glioblastomas harboring immunosuppressive and aggressive ECM characteristics. Zhong Nan Da Xue Xue Bao Yi Xue Ban 43(4):368-382, 2018. e-Pub 2018. PMID: 29774872.
      35. Hwang I, Cao D, Na Y, Kim DY, Zhang T, Yao J, Oh H, Hu J, Zheng H, Yao Y, Paik J. Far Upstream Element-Binding Protein 1 Regulates LSD1 Alternative Splicing to Promote Terminal Differentiation of Neural Progenitors. Stem Cell Reports 10(4):1208-1221, 2018. e-Pub 2018. PMID: 29606613.
      36. Zhang P, He D, Xu Y, Hou J, Pan BF, Wang Y, Liu T, Davis CM, Ehli EA, Tan L, Zhou F, Hu J, Yu Y, Chen X, Nguyen TM, Rosen JM, Hawke DH, Ji Z, Chen Y. Genome-wide identification and differential analysis of translational initiation. Nat Commun 8(1):1749, 2017. e-Pub 2017. PMID: 29170441.
      37. Wang Q, Hu B, Hu X, Kim H, Squatrito M, Scarpace L, deCarvalho AC, Lyu S, Li P, Li Y, Barthel F, Cho HJ, Lin YH, Satani N, Martinez-Ledesma E, Zheng S, Chang E, Sauvé CG, Olar A, Lan ZD, Finocchiaro G, Phillips JJ, Berger MS, Gabrusiewicz KR, Wang G, Eskilsson E, Hu J, Mikkelsen T, DePinho RA, Muller F, Heimberger AB, Sulman EP, Nam DH, Verhaak RGW. Tumor Evolution of Glioma-Intrinsic Gene Expression Subtypes Associates with Immunological Changes in the Microenvironment. Cancer Cell 32(1):42-56.e6, 2017. e-Pub 2017. PMID: 28697342.
      38. Barthel FP, Wei W, Tang M, Martinez-Ledesma E, Hu X, Amin SB, Akdemir KC, Seth S, Song X, Wang Q, Lichtenberg T, Hu J, Zhang J, Zheng S, Verhaak RG. Systematic analysis of telomere length and somatic alterations in 31 cancer types. Nat Genet 49(3):349-357, 2017. e-Pub 2017. PMID: 28135248.
      39. Boutin AT, Liao WT, Wang M, Hwang SS, Karpinets TV, Cheung H, Chu GC, Jiang S, Hu J, Chang K, Vilar E, Song X, Zhang J, Kopetz S, Futreal A, Wang YA, Kwong LN, DePinho RA. Oncogenic Kras drives invasion and maintains metastases in colorectal cancer. Genes Dev 31(4):370-382, 2017. e-Pub 2017. PMID: 28289141.
      40. Hu B, Wang Q, Wang YA, Hua S, Sauvé CG, Ong D, Lan ZD, Chang Q, Ho YW, Monasterio MM, Lu X, Zhong Y, Zhang J, Deng P, Tan Z, Wang G, Liao WT, Corley LJ, Yan H, Zhang J, You Y, Liu N, Cai L, Finocchiaro G, Phillips JJ, Berger MS, Spring DJ, Hu J, Sulman EP, Fuller GN, Chin L, Verhaak RG, DePinho RA. Epigenetic Activation of WNT5A Drives Glioblastoma Stem Cell Differentiation and Invasive Growth. Cell 167(5):1281-1295.e18, 2016. e-Pub 2016. PMID: 27863244.
      41. Shingu T, Ho AL, Yuan L, Zhou X, Dai C, Zheng S, Wang Q, Zhong Y, Chang Q, Horner JW, Liebelt BD, Yao Y, Hu B, Chen Y, Fuller GN, Verhaak RG, Heimberger AB, Hu J. Qki deficiency maintains stemness of glioma stem cells in suboptimal environment by downregulating endolysosomal degradation. Nat Genet. e-Pub 2016. PMID: 27841882.
      42. Shingu T, Holmes L, Henry V, Wang Q, Latha K, Gururaj AE, Gibson LA, Doucette T, Lang FF, Rao G, Yuan L, Sulman EP, Farrell NP, Priebe W, Hess KR, Wang YA, Hu J, Bögler O. Suppression of RAF/MEK or PI3K synergizes cytotoxicity of receptor tyrosine kinase inhibitors in glioma tumor-initiating cells. J Transl Med 14(1):46. e-Pub 2016. PMID: 26861698.
      43. Liebelt BD, Shingu T, Zhou X, Ren J, Shin SA, Hu AJ. Glioma Stem Cells: Signaling, Microenvironment, and Therapy. Stem Cells International 2016(10.1155):10, 2016. e-Pub 2016.
      44. Kim H, Zheng S, Amini SS, Virk SM, Mikkelsen T, Brat DJ, Grimsby J, Sougnez C, Muller F, Hu J, Sloan AE, Cohen ML, Van Meir EG, Scarpace L, Laird PW, Weinstein JN, Lander ES, Gabriel S, Getz G, Meyerson M, Chin L, Barnholtz-Sloan JS, Verhaak RG. Whole-genome and multisector exome sequencing of primary and post-treatment glioblastoma reveals patterns of tumor evolution. Genome Res 25(3):316-27, 2015. e-Pub 2015. PMID: 25650244.
      45. Yao Y, Hu J, Shen Z, Yao R, Liu S, Li Y, Cong H, Wang X, Qiu W, Yue L. MiR-200b expression in breast cancer: a prognostic marker and act on cell proliferation and apoptosis by targeting Sp1. J Cell Mol Med. e-Pub 2015. PMID: 25639535.
      46. Shingu T, Jaskelioff M, Yuan L, Ding Z, Protopopov A, Kost-Alimova M, Hu J. Utilizing murine inducible telomerase alleles in the studies of tissue degeneration/regeneration and cancer. J Vis Exp(98), 2015. e-Pub 2015. PMID: 25938254.
      47. Hu J, Ho AL, Yuan L, Hu B, Hua S, Hwang SS, Zhang J, Hu T, Zheng H, Gan B, Wu G, Wang YA, Chin L, DePinho RA. From the Cover: Neutralization of terminal differentiation in gliomagenesis. Proc Natl Acad Sci U S A 110(36):14520-7, 2013. e-Pub 2013. PMID: 23918370.
      48. Muller FL, Colla S, Aquilanti E, Manzo VE, Genovese G, Lee J, Eisenson D, Narurkar R, Deng P, Nezi L, Lee MA, Hu B, Hu J, Sahin E, Ong D, Fletcher-Sananikone E, Ho D, Kwong L, Brennan C, Wang YA, Chin L, DePinho RA. Passenger deletions generate therapeutic vulnerabilities in cancer. Nature 488(7411):337-42, 2012. e-Pub 2012. PMID: 22895339.
      49. Chen AJ, Paik JH, Zhang H, Shukla SA, Mortensen R, Hu J, Ying H, Hu B, Hurt J, Farny N, Dong C, Xiao Y, Wang YA, Silver PA, Chin L, Vasudevan S, Depinho RA. STAR RNA-binding protein Quaking suppresses cancer via stabilization of specific miRNA. Genes Dev 26(13):1459-72, 2012. e-Pub 2012. PMID: 22751500.
      50. Ying H, Kimmelman AC, Lyssiotis CA, Hua S, Chu GC, Fletcher-Sananikone E, Locasale JW, Son J, Zhang H, Coloff JL, Yan H, Wang W, Chen S, Viale A, Zheng H, Paik JH, Lim C, Guimaraes AR, Martin ES, Chang J, Hezel AF, Perry SR, Hu J, Gan B, Xiao Y, Asara JM, Weissleder R, Wang YA, Chin L, Cantley LC, DePinho RA. Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell 149(3):656-70, 2012. e-Pub 2012.
      51. Ding Z, Wu CJ, Jaskelioff M, Ivanova E, Kost-Alimova M, Protopopov A, Chu GC, Wang G, Lu X, Labrot ES, Hu J, Wang W, Xiao Y, Zhang H, Zhang J, Zhang J, Gan B, Perry SR, Jiang S, Li L, Horner JW, Wang YA, Chin L, DePinho RA. Telomerase reactivation following telomere dysfunction yields murine prostate tumors with bone metastases. Cell 148(5):896-907, 2012. e-Pub 2012.
      52. Hu J, Hwang SS, Liesa M, Gan B, Sahin E, Jaskelioff M, Ding Z, Ying H, Boutin AT, Zhang H, Johnson S, Ivanova E, Kost-Alimova M, Protopopov A, Wang YA, Shirihai OS, Chin L, DePinho RA. Antitelomerase therapy provokes ALT and mitochondrial adaptive mechanisms in cancer. Cell 148(4):651-63, 2012. e-Pub 2012. PMID: 22341440.
      53. Gan B, Hu J, Jiang S, Liu Y, Sahin E, Zhuang L, Fletcher-Sananikone E, Colla S, Wang YA, Chin L, Depinho RA. Lkb1 regulates quiescence and metabolic homeostasis of haematopoietic stem cells. Nature 468(7324):701-4, 2010. e-Pub 2010. PMID: 21124456.
      54. Gan B, Lim C, Chu G, Hua S, Ding Z, Collins M, Hu J, Jiang S, Fletcher-Sananikone E, Zhuang L, Chang M, Zheng H, Wang YA, Kwiatkowski DJ, Jr KW, Signoretti S, DePinho RA. FoxOs enforce a progression checkpoint to constrain mTORC1-activated renal tumorigenesis. Cancer Cell 18(5):472-84, 2010. e-Pub 2010. PMID: 21075312.
      55. Zheng H, Ying H, Wiedemeyer R, Yan H, Quayle SN, Ivanova EV, Paik JH, Zhang H, Xiao Y, Perry SR, Hu J, Vinjamoori A, Gan B, Sahin E, Chheda MG, Brennan C, Wang YA, Hahn WC, Chin L, DePinho RA. PLAGL2 regulates Wnt signaling to impede differentiation in neural stem cells and gliomas. Cancer Cell 17(5):497-509, 2010. e-Pub 2010. PMID: 20478531.
      56. Ying H, Zheng H, Scott K, Wiedemeyer R, Yan H, Lim C, Huang J, Dhakal S, Ivanova E, Xiao Y, Zhang H, Hu J, Stommel JM, Lee MA, Chen AJ, Paik JH, Segatto O, Brennan C, Elferink LA, Wang YA, Chin L, DePinho RA. Mig-6 controls EGFR trafficking and suppresses gliomagenesis. Proc Natl Acad Sci U S A 107(15):6912-7, 2010. e-Pub 2010. PMID: 20351267.
      57. Hu J, Zacharek S, He YJ, Lee H, Shumway S, Duronio RJ, Xiong Y. WD40 protein FBW5 promotes ubiquitination of tumor suppressor TSC2 by DDB1-CUL4-ROC1 ligase. Genes Dev 22(7):866-71, 2008. e-Pub 2008. PMID: 18381890.
      58. He Y, McCall CM, Hu J, Zeng Y, Xiong Y. DDB1 functions as a linker to recruit receptor WD40 proteins to CUL4-ROC1 ubiquitin ligases. Genes Dev 20(21):2949-54, 2006. e-Pub 2006. PMID: 17079684.
      59. Hu J, Xiong Y. An evolutionarily conserved function of proliferating cell nuclear antigen for Cdt1 degradation by the Cul4-Ddb1 ubiquitin ligase in response to DNA damage. J Biol Chem 281(7):3753-6, 2006. e-Pub 2006. PMID: 16407242.

      Review Articles

      1. Xing, J, McKenzie, T, Hu, J. Lipid-Laden Microglia. Cells 14(16), 2025. e-Pub 2025. PMID: 40862760.
      2. Frank, ML, Lu, K, Erdogan, C, Han, Y, Hu, J, Wang, T, Heymach, JV, Zhang, J, Reuben, A. T-Cell Receptor Repertoire Sequencing in the Era of Cancer Immunotherapy. Clinical Cancer Research 29(6):994-1008, 2023. e-Pub 2023. PMID: 36413126.
      3. Barnes-Vélez, JA, Aksoy Yasar, FB, Hu, J. Myelin lipid metabolism and its role in myelination and myelin maintenance. Innovation 4(1), 2023. e-Pub 2023. PMID: 36588745.
      4. Güran, E, Hu, J, Wefel, JS, Chung, C, Cata, JP. Perioperative considerations in patients with chemotherapy-induced cognitive impairment. British journal of anaesthesia 129(6):909-922, 2022. e-Pub 2022. PMID: 36270848.
      5. Zorrilla-Veloz, RI, McKenzie, T, Palacios, BE, Hu, J. Nuclear hormone receptors in demyelinating diseases. Journal of Neuroendocrinology 34(7), 2022. e-Pub 2022. PMID: 35734821.
      6. Privorotskiy A, Bhavsar SP, Lang FF, Hu J, Cata JP. Impact of anesthesia and analgesia techniques on glioblastoma progression. A narrative review. Neurooncol Adv 2(1):vdaa123, 2020. e-Pub 2020. PMID: 33205044.

      Other Articles

      1. Hwang, WL, Perrault, EN, Birbrair, A, Mattson, BJ, Gutmann, DH, Mabbott, D, Cukierman, E, Repasky, EA, Sloan, EK, Zong, H, Demir, IE, Saloman, JL, Borniger, JC, Hu, J, Dietrich, J, Breunig, JJ, Çifcibaşı, K, Ahmad Kasm, KA, Valiente, M, Wintermark, M, Acharya, M, Scheff, NN, D'Silva, NJ, Vermeer, PD, Wong, RJ, Talbot, S, Hervey-Jumper, S, Wang, TC, Ye, Y, Pan, Y, Bunimovich, YL, Amit, M Integrating priorities at the intersection of cancer and neuroscience. Cancer cell 43(1):1-5, 2025. PMID: 39423816.
      2. Barnes-Velez JA, Pena Seneriz YL, Scott KA, Guan Y, Hu J Peroxisomal integrity in myeloid cells is required for myelin debris clearance and remyelination. J Clin Invest.

      Editorials

      1. Hu, J. Why We Fail at Cancer Clinical Trials so Often. Anesthesiology 140(3):349-351, 2024. PMID: 38349758.
      Read More
      Less

      Patient Reviews


      CV information above last modified July 22, 2026

      Request an Appointment

      Whether you are ready to make an appointment now or have questions for our expert team, we are standing by to help.
      Learn more

      Related Links

      • Hu Laboratory

      • Cancer Biology department

      • Discovery Science division

      Clinical Trials

      Our patients have access to clinical trials offering promising new treatments that cannot be found anywhere else.
      Learn more

      Help #EndCancer

      Give Now

      Your gift will help make a tremendous difference.
      Donate

      Donate Blood

      Our patients depend on blood and platelet donations.

      Make an appointment

      Shop UT MD Anderson

      Show your support for our mission through branded merchandise.

      View products
      Subscribe to our Cancerwise newsletter
      UT MD Anderson logoUT MD Anderson logo
      • Explore
      • Patients & Family
      • Prevention & Screening
      • Donors & Volunteers
      • For Physicians
      • Research
      • Education & Training
      • Clinical Trials
      • Languages
      • About
      • About UT MD Anderson
      • Careers
      • Blog
      • Newsroom
      • Editorial Standards
      • For Employees
      • Merchandise
      • Title IX Reporting (Sexual Misconduct)
      • Price Transparency
      • Finding Your Way
      • Our Doctors
      • Locations
      • Directions
      • Sitemap
      • DIGITAL ACCESSIBILITY
      • Accessibility Policy MD Anderson works with Level Access to ensure our website is accessible and functional for all users. Free assistive technology is provided for people with physical disabilities. To learn more or to download the assistive technology tool, visit https://www.levelaccess.com/MDAnderson
      • GET IN TOUCH
      • Call
        1-877-632-6789
      • Ask a question
      • Stay Connected
      • Cancerwise Podcast
      • More
      • Website Privacy Policy
      • Legal Statement & Policies
      • Reports to the State
      • Emergency Alert Information
      • State of Texas Links
      • Our Cancer Network
      • Vendors & Suppliers
      UT MD Anderson logo
      The mission of The University of Texas MD Anderson Cancer Center is to eliminate cancer in Texas, the nation, and the world through outstanding programs that integrate patient care, research and prevention, and through education for undergraduate and graduate students, trainees, professionals, employees and the public.

      © 2026 The University of Texas MD Anderson Cancer Center. All rights reserved.

      Top